top of page
Search

Aug 13, 2021

Updated: Aug 17, 2021

Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Clindamycin Phosphate Gel USP, 1% (Once-A-Day) in 75 mL bottle a generic version of reference listed drug Clindagel® (clindamycin phosphate) topical gel, 1%. For more updates, please visit the products page or email us directly at info@solaris-pharma.com

236 views0 comments

Recent Posts

See All

Solaris Pharma Corporation is pleased to announce the product approval of Tazarotene Gel, 0.05% and 0.1%.

Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Fluocinolone Acetonide Oil, 0

bottom of page